Business Context and Reporting Period
This Form 8-K Current Report was filed by Altimmune, Inc. on July 11, 2018. The filing details a material definitive agreement entered into on the same date involving the exchange of preferred stock and warrants for common stock with certain investors, including Novartis Bioventures Ltd., Truffle Capital S.A.S., and HealthCap V L.P.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or operating margins. The transaction involves the following specific financial and equity figures:
- First Closing: Issuance of 963,711 shares of Common Stock and payment of $22,241 in cash in exchange for all Series B Redeemable Convertible Preferred Stock held by the Investors.
- Second Closing (Pending): Anticipated issuance of an additional 4,351,136 shares of Common Stock in exchange for Existing Warrants held by the Investors.
- Remaining Warrants: Following the exchange, investors not party to the agreement will hold warrants to purchase 75,995 shares of Common Stock.
Material Changes
The primary material change is the restructuring of the Company's capital structure regarding the Investors:
- Termination of Preferred Stock: Upon completion of the exchange, the Company will have no shares of Series B Convertible Preferred Stock outstanding.
- Termination of Warrants: All Existing Warrants held by the participating Investors will be deemed satisfied and terminated.
- Agreement Termination: All obligations under the August 16, 2017 Securities Purchase Agreement and the Certificate of Designations for Series B Preferred Stock relating to these Investors will be terminated.
Outlook, Management Commentary, and Corporate Governance
Transaction Timeline: The Second Closing is anticipated to occur in the third quarter of 2018, subject to stockholder approval and NASDAQ Global Market rules.
Investor Voting Rights: The Exchange Agreements require Investors to vote their Common Stock at the 2018 Annual Meeting for all directors nominated by the Board and in accordance with Board recommendations on other proposals, with an exception for the proposal to issue the Exchange Shares.
Annual Meeting Update: The 2018 Annual Meeting of Stockholders is scheduled for or about August 30, 2018. The record date is set for July 23, 2018. Due to the change in meeting date, the deadline for stockholder proposals under Rule 14a-8 and director nominations under the Bylaws is July 26, 2018.
Investor Verification Checklist
- Verify the status of stockholder approval required for the issuance of the 4,351,136 Warrant Exchange Shares.
- Confirm the exact date of the Second Closing to assess dilution impact in the third quarter of 2018.
- Review the full text of the Form of Exchange Agreement (Exhibit 10.1) for specific covenants and voting restrictions.
- Monitor the 2018 Annual Meeting proxy materials for the final outcome of the stockholder vote on the share issuance.